The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
December 5th 2023
The approval marks levothyroxine sodium as the only FDA-granted LT4 therapy that does not have a labeled interaction with PPIs and can be taken 15 minutes prior to eating breakfast.
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
November 21st 2023Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Read More